Myrica esculenta Buch.-Ham. (ex D. Don): A Review on its Phytochemistry, Pharmacology and Nutritional Potential.

Myrica esculenta is an important ethnomedicinal plant used in the traditional system of medicine and as an important nutraceutical. Several studies on the plant justify its use in alternative systems of medicine and establish a scientific rationale for its possible therapeutic application. The plant contains a range of biologically active classes of compounds, particularly diarylheptanoids, flavonoids, terpenes, tannins, and glycosides. The nutraceutical potential of the plant can be particularly attributed to its fruit, and several studies have demonstrated the presence of carbohydrates, proteins, fats, fiber content, and minerals like sodium, potassium, calcium, manganese, iron, copper, and zinc, in it. The current review aims to provide complete insight into the phytochemistry, pharmacological potential, and nutritional potential of the plant, which would not only serve as a comprehensive source of information but also will highlight the scope of isolation and evaluation of these molecules for various disease conditions.

Assessment of Anti-inflammatory Activity of 3-Acetylmyricadiol in LPSStimulated Raw 264.7 Macrophages.

BACKGROUND: Pentacyclic triterpenoids are a biologically active class of phytoconstituents with diverse pharmacological activities, including anti-inflammatory action. OBJECTIVE: In the current study, we isolated 3-Acetylmyricadiol, a pentacyclic triterpenoid, from the ethyl acetate bark extract of Myrica esculenta and evaluated it for anti-inflammatory potential. METHODS: The ethyl acetate bark extract of the M. esculenta was subjected to column chromatography to isolate 3-Acetylmyricadiol. MTT assay was performed to check cell viability. The production of proinflammatory mediators like nitric oxide, IL-6, TNF-α were observed after the administration of 5, 10, 20 µM of 3-Acetylmyricadiol in LPS-activated raw 246.7 macrophages by the reported methods. RESULTS: MTT assay indicated more than 90% cell viability up to 20 µM of 3-Acetylmyricadiol. The administration of 3-Acetylmyricadiol inhibited the production of nitric oxide, IL-6, TNF-α in a dose-dependent manner significantly in comparison to LPS treated cells. The maximum effect was observed at 20 µM of 3-Acetylmyricadiol which resulted in 52.37, 63.10, and 55.37 % inhibition of nitric oxide, IL-6, and TNF-α, respectively. CONCLUSION: Our study demonstrated the anti-inflammatory action of 3-Acetylmyricadiol and can serve as a potential candidate in the development of the clinically efficient anti-inflammatory molecule.

Pharmacognostic and pharmacological evaluation of Eulaliopsis binata plant extracts by measuring in vitro/in vivo safety profile and anti-microbial potential.

The present investigation emphasizes the pharmacognostic and phytochemical screening of Eulaliopsis binata and further evaluates the extracts of this plant for toxicological profile and anti-bacterial potential based on in vivo/in vitro assays. Microscopy, powder characteristics of the leaf material, and physicochemical and phytochemical screening were assessed for pharmacognostic evaluation. Dry leaves of Eulaliopsis binata were extracted using different solvents (methanol, ethyl acetate, and hexane), and the extracts obtained were further investigated for in vitro/in vivo toxicological study. Moreover, acute toxicity was assessed by evaluating the anti-oxidant defense system and anatomical damage in vital organs. In addition, anti-bacterial activity of all the extracts was assessed by the Kirby-Bauer method. Physicochemical and microscopic observations showed the unique identification mark for leaf powder and leaf transverse section. Phytochemical investigation evidenced the presence of flavonoids and phenolic contents in the methanolic extract. All extracts were found to be hemocompatible and exhibited no induction of behavioral alteration and no alteration in the anti-oxidant potential and anatomical structure of the vital organs. On the other hand, the methanolic extract showed a significant upsurge in the reduced glutathione level, whereas all extracts showed significant anti-bacterial potential in a dose-dependent manner. Eulaliopsis binata has inimitable pharmacognostical characteristics, good safety profile and significant anti-oxidant and anti-bacterial potential that show immense possibility for its further investigation for pharmacological use.

Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.

BACKGROUND: Noscapine, a naturally occurring antitussive phthalideisoquinoline alkaloid, is a tubulin-binding agent currently in Phase I/II clinical trials for anticancer therapy. Unlike currently available antimitotics such as taxanes and vincas, noscapine is water-soluble, well tolerated, and shows no detectable toxicity. OBJECTIVE: The goal was to develop a simple, sensitive, quantitative, selective, and less time-consuming high-performance liquid chromatography (HPLC) method for determination of noscapine and to study its pharmacokinetics in mice models. METHOD: Noscapine was extracted from mice plasma using the protein-precipitation method and detected using a reversed-phase C8 column with mobile phase consisting of 35% acetonitrile and 65% ammonium acetate buffer (pH 4.5) at 232 nm wavelength. Pharmacokinetic studies of noscapine were performed in mice following intravenous bolus at 10 mg/kg and oral administrations at 75, 150, and 300 mg/kg. RESULTS: The standard curves for noscapine estimation were linear between 390 and 50,000 ng/ml (lower limit of quantification was 390 ng/ml) and the recovery was approximately 80%. Following 10 mg/kg intravenous dose, mean plasma concentrations of 7.88 microg/ml were achieved at 5 min in mice and declined with undetectable levels at 4 h. The mean total body clearance was 4.78 l/h. The mean volume of distribution (V (d)) was 5.05 l. Non-compartmental analysis yielded the mean area under the plasma concentration-time curve (AUC) for noscapine as 53.42, 64.08, and 198.35 h microg/ml reaching maximum plasma concentrations (C (max)) of 12.74, 23.24, and 46.73 microg/ml at a t (max) of 1.12, 1.50, and 0.46 h at the linearly increasing dose levels. CONCLUSION: A rapid and simple HPLC/UV method for the quantification of noscapine in plasma has been developed to study pharmacokinetics of noscapine at tumor-suppressive doses in the mouse. Since orally available anticancer drugs are rare, therefore, noscapine, an innocuous agent, having a mean oral bioavailability of 31.5% over the studied dose range merits its further advancement in humans for anticancer therapy.